Screening of Hepatoprotective Drugs

Definition, rationale & experimental design

• Hepatoprotective screening — systematic in vitro and in vivo evaluation of a candidate for its capacity to prevent, attenuate or reverse chemically- or biologically-induced liver injury, measured against a validated toxin insult and a positive-control reference drug.
• Why the liver is a screening priority — it is the principal organ of xenobiotic biotransformation and a frequent target of drugs, industrial toxins and plant/fungal poisons; the very large candidate pool (especially the Indian herbal-hepatoprotective literature) demands a reproducible bench pipeline.
• Two injury paradigms are screened separately — because they model different human diseases:
  • Acute hepatocellular necrosis / hepatitis — a single or few toxin doses cause centrilobular necrosis with a rapid rise in leakage enzymes; screens for cytoprotection (galactosamine, allyl alcohol, acute CCl₄, paracetamol).
  • Chronic fibrosis / cirrhosis — repeated toxin dosing over weeks drives collagen deposition; screens for antifibrotic / fibrosuppressive activity (chronic CCl₄, bile-duct ligation, thioacetamide, dimethylnitrosamine).
• Group design — rats (Wistar/Sprague-Dawley, 100–250 g) are randomised into Group 1 normal/vehicle control · Group 2 toxin-only (injury control) · Group 3 toxin + reference standard (silymarin) · Groups 4–5 toxin + test drug at graded doses.
• Protective-drug window — a prophylactic/co-treatment design gives the agent before and during toxin exposure to test prevention (drug 30–60 min prior to induction); a curative design gives the drug after injury is established. Injury is quantified biochemically, functionally and histologically at a fixed sacrifice endpoint.